Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

30 Mar 2022
Regulated information - denominator
Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA

Oxurion has successfully raised EUR >10 million from leading US and European healthcare...

28 Mar 2022
Event
Oxurion to Participate in Needham Virtual Healthcare Conference

Leuven, BELGIUM, Boston, MA, US - MARCH 28, 2022 – 8....

25 Mar 2022
Regulated information
Oxurion Publishes 2021 Annual Report

Leuven, BELGIUM, Boston, MA, US - March 25,2022 – 09.00...

17 Mar 2022
Regulated information
Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG

 

Leuven, Belgium, Boston, MA, US - March 17,2022 – 07.00 PM...

7 Mar 2022
Investors
Oxurion Successfully Closes EUR >10 Million in Private Placement

Leuven, BELGIUM, Boston, MA, US - MARCH 7, 2022 – 10....

3 Mar 2022
Regulated information - Inside information; Investors
Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement

Leuven, BELGIUM, Boston, MA, US - MARCH 3, 2022 – 08:...

22 Feb 2022
Regulated information - denominator; Capital structure
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA

Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310

Info@oxurion.com